SBIR Phase II: Purification of Metallic Nitride Nanomaterials by Chemical Separation

SBIR 第二阶段：通过化学分离纯化金属氮化物纳米材料

• 批准号: 0349691
• 负责人: Stephen Wilson
• 金额: $ 50万
• 依托单位: Luna Innovations, Incorporated
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-01-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0349691&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Purification; Metallic

This Small Business Innovation Research (SBIR) Phase II project will involve production and purification of a powerful Magnetic Resonance Imaging (MRI) contrast agent based on a newly discovered nanomaterial (Trimetasphere), consisting of a metallic nitride nanocluster inside a fullerene type cage. Trimetaspheres recently demonstrated a factor of 21 times improved relaxivity over currently used MRI contrast agents. The project will involve designing and building a powder-feed continuous reactor, including large rod capability, developing chemically-based separations techniques and optimizing heat treatment of the chemically separated Trimetaspherses mixtures. The nanoproduction and chemical-based separations techniques for these Trimetasphere nanomaterials will provide the basis for the large-scale production of the Trimetasphere based MRI contrast agents.Commercially, these Trimetaspheres have tremendous medical applications that will benefit US citizens with better medical care through improved diagnostics, new pharmaceuticals, and simultaneous diagnostic and treatment reagents, at a fraction of current cost. The development of more sensitive contrast agents, if translated into smaller, less expensive MRI instruments, will open entirely new markets for the equipment manufacturers.

这个小企业创新研究（SBIR）第二阶段项目将涉及基于新发现的纳米材料（Trimetasphere）的强大磁共振成像（MRI）造影剂的生产和纯化，该材料由富勒烯型笼内的金属氮化物纳米簇组成。 Trimetatheres最近证明了比目前使用的MRI造影剂提高21倍的弛豫率。 该项目将涉及设计和建造一个粉末进料连续反应器，包括大棒能力，开发基于化学的分离技术，并优化化学分离的Trimetaspherses混合物的热处理。 这些Trimetasphere纳米材料的纳米生产和化学分离技术将为大规模生产Trimetasphere MRI造影剂提供基础。在商业上，这些Trimetaspheres具有巨大的医疗应用，通过改进诊断，新药和同时诊断和治疗试剂，以当前成本的一小部分，将使美国公民获得更好的医疗保健。 更灵敏的造影剂的开发，如果转化为更小，更便宜的MRI仪器，将为设备制造商打开全新的市场。